[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-malignant-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-malignant-neoplasm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100587404","navigation-interventions-to-improve-cascade-genetic-testing-among-relatives-of-patients-with-hereditary-cancer-syndromes-100587404",false,"NCT06927947","Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes","Testing Effectiveness of Navigation Interventions to Increase Uptake of Cascade Genetic Testing Among Relatives of Individuals Diagnosed With Hereditary Cancer Syndromes","Inclusion Criteria:\n\n* PROBANDS: Clinically confirmed autosomal dominant pathogenic germline variant (PGV) associated with a hereditary cancer syndrome\n* PROBANDS: Previous evaluation by the University of Michigan (U-M) Cancer Genetics Clinic\n* PROBANDS: ≥ 18 years old\n* PROBANDS: Able to speak and read English\n* PROBANDS: Access to the internet\n* RELATIVES: Biological relative of proband\n* RELATIVES: ≥ 18 years old\n* RELATIVES: Able to speak and read English\n* RELATIVES: Access to the internet\n* RELATIVES: Have not completed germline genetic testing, per self-report at baseline\n\nExclusion Criteria:\n\n* RELATIVES: Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider, per self-report at baseline",true,"ALL","18 Years",{"count":20,"type":21},625,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.",[27,28],"Hereditary Malignant Neoplasm","Hereditary Neoplastic Syndrome","RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":35,"type":33},"2025-09-23",{"date":37,"type":21},"2026-09-30",{"name":39,"class":40},"University of Michigan Rogel Cancer Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100498582","provider-mediated-communication-of-genetic-testing-results-to-at-risk-relatives-of-cancer-patients-to-improve-genetic-counseling-and-testing-rates-family-hope-study-100498582","NCT05772130","Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study","Family HOPE Study (Hereditary Lynch Syndrome Opportunities for Participation &Amp; Engagement)","Inclusion Criteria:\n\n* PATIENTS: Enrolled in City of Hope (COH) institutional review board (IRB) 07047 or have been seen by COH Genetics for genetic testing\n* PATIENTS: Have an pathogenic\u002F likely pathogenic germline variant\n* PATIENTS: Fluent in English\n* PATIENTS: Age \\>= 18 years\n* PATIENTS: Willing to provide contact information for eligible first-degree relatives\n* PATIENTS: \\>= 2 first-degree relatives that are eligible for genetic testing and reside in the United States of America\n* FIRST-DEGREE RELATIVES: Proband is a COH patient and has consented to this study\n* FIRST-DEGREE RELATIVES: First-degree relative of proband\n* FIRST-DEGREE RELATIVES: Resides within the United States\n* FIRST-DEGREE RELATIVES: Has not undergone genetic testing for the known familial variant\n* FIRST-DEGREE RELATIVES: Are fluent in English\n* FIRST-DEGREE RELATIVES: Age \\>= 18 years\n\nExclusion Criteria:\n\n* PATIENTS: Unable to provide informed consent\n* PATIENTS: =\\\u003C 2 at-risk first-degree relatives who are eligible for genetic testing and\u002For reside within the United States\n* PATIENTS: Unwilling to provide contact information for family members\n* FIRST-DEGREE RELATIVES: Unable or unwilling to provide informed consent\n* FIRST-DEGREE RELATIVES: Have undergone genetic testing for the known familial variant\n* FIRST-DEGREE RELATIVES: Resides outside of the United States",{"count":50,"type":21},240,[24],"This clinical trial tests whether provider-mediated communication of genetic testing results to at-risk relatives of cancer patients can help improve genetic counseling and testing rates. Approximately 15% of people with cancer have an inherited form of cancer due to changes in a gene that they have inherited from one of their parents. These changes increase a person's risk for developing cancer. Most people who have an inherited harmful change in a cancer risk gene don't know that they have it and are therefore not able to get the health care that they need. The primary reason for this problem has been a lack of genetic counseling and testing for cancer patients and patients with a strong family history of cancer. Another reason for this lack of awareness is that, when cancer runs in a family, the patient who carries the gene change usually has to communicate the genetic risk information to their family members. When this process doesn't work well, family members may not know that they need to get genetic testing and then may not get potentially life-saving care. Provider-mediated contact to discuss genetic test results may help improve rates of genetic testing among at-risk relatives of patients with a family cancer syndrome.",[54,27,55],"Hematopoietic and Lymphoid System Neoplasm","Malignant Solid Neoplasm","2025-12-31",{"date":58,"type":33},"2026-01-05",{"date":60,"type":33},"2023-02-14",{"date":62,"type":21},"2026-12-21",{"name":64,"class":40},"City of Hope Medical Center"]